Associated tags: Patient, ALS, Caregiver, Research, Diagnosis, AI, Amyotrophy, Medical device, Neurology, Disease
Locations: SEATTLE, WA, US, NCR
Research,
Neurology,
Harvard Medical School,
Synthetic media,
Machine learning,
Government,
Regeneration,
Prevalence,
Massachusetts General Hospital,
Science,
Environment,
MIT,
Data science,
SAN,
Knowledge,
Biomarker,
History,
Hope,
Doctor of Philosophy,
LLM,
Vision 2030,
Hub,
Ecosystem,
Drug development,
Navar,
Frontotemporal dementia,
Artificial intelligence,
Generative,
Mass,
Medicine,
Medical device The Vision 2030 AI Hub will have a laser focus on "repair and regeneration," aiming to distinguish the organization in the ALS research landscape.
Key Points:
- The Vision 2030 AI Hub will have a laser focus on "repair and regeneration," aiming to distinguish the organization in the ALS research landscape.
- The Vision 2030 AI Hub epitomizes this momentous convergence—where the cumulative advances in ALS research and technology coalesce, heralding a new epoch of hope and discovery.
- The Vision 2030 AI Hub motivates giving and fundraising, showcasing an innovative operating model that emphasizes urgency in tackling ALS and other disorders.
- For more information about EverythingALS, Vision 2030, and the AI Hub visit http://www.v2030.org or email us at [email protected] .
Retrieved on:
Tuesday, January 30, 2024
Pals,
Life expectancy,
PHD,
Research,
AI,
Biomarker,
Caregiver,
Machine learning,
Patient,
Digital,
Diagnosis,
Speech,
Massachusetts Institute of Technology,
Disease,
Quality of life,
ALS,
Research design Participants of the Austen Speech Study are hopeful the open data leads to a quicker way to diagnose the disease and even potential treatment options.
Key Points:
- Participants of the Austen Speech Study are hopeful the open data leads to a quicker way to diagnose the disease and even potential treatment options.
- “ALS has caused my speech to be altered, which is a very typical characteristic of Bulbar ALS,” said ALS patient and Austen Speech Study participant Jack Gray.
- “Since my diagnosis of ALS/PLS, I have participated in the EverythingALS Austen Speech Study.
- For more information and to access the open data from the Austen Speech Study, please visit: https://www.everythingals.org/available-data .
Retrieved on:
Wednesday, September 27, 2023
Robert Larner College of Medicine,
Student society,
University,
CITI,
Research,
Mentorship,
Medicine,
Trial of the century,
Student,
Behavior,
Christians,
Fellow,
Fellows,
Neurology,
ECAS,
ALS,
Citizen science,
People to People Student Ambassador Program,
Nursing SEATTLE, Sept. 27, 2023 (GLOBE NEWSWIRE) -- EverythingALS, a citizen science research organization dedicated to developing cure for ALS, announced today the Student Fellow Scholarship Awards and the expansion and continued enrollment of student Ambassadors program.
Key Points:
- SEATTLE, Sept. 27, 2023 (GLOBE NEWSWIRE) -- EverythingALS, a citizen science research organization dedicated to developing cure for ALS, announced today the Student Fellow Scholarship Awards and the expansion and continued enrollment of student Ambassadors program.
- Through the Fellows and Student Ambassadors programs, students learn the importance and understanding of human-centered study design to improve research participation and outcomes.
- They develop an understanding of observational and clinical study management, and connect program mentors and scientific thought leaders to co-host EverythingALS community events.
- Upon completion of the programs, Fellows of this program receive a scholarship, while Student Ambassadors receive referrals and/or letters of recommendation.
Biotechnology,
Health,
Neurology,
Biometrics,
Other Health,
Other Philanthropy,
Philanthropy,
Research,
Telemedicine,
Virtual Medicine,
Medical Devices,
Genetics,
Health Technology,
Foundation,
Science,
Cognition,
Partnership,
MGH,
ALS Association,
Movement,
Walking,
Diagnosis,
Hospital,
AI,
Massachusetts General Hospital,
ALS,
Medical device ALS is a rare and terminal neurological disease that robs people of their ability to move, speak, and eat in just a few years.
Key Points:
- ALS is a rare and terminal neurological disease that robs people of their ability to move, speak, and eat in just a few years.
- ALS diagnosis takes on average 12 to 18 months and we aim to change that.
- The data from this comprehensive monitoring will be used to identify early diagnostic markers of ALS.
- The open innovation concept is leveraged by the larger communities of AI engineers, researchers, and neurologists to spur progress in finding early digital diagnostic markers.
Technology,
Research,
Neurology,
Professional Services,
Biotechnology,
Health,
Data Analytics,
Science,
Artificial Intelligence,
Frontotemporal dementia,
Partnership,
Stage 4,
Therapy,
ALS,
Cureall, Missouri,
History,
Government,
Organization,
Acquisition,
Patient,
Amyotrophy,
Artificial intelligence,
Diagnosis,
Ecosystem,
AI,
FTD,
Data science,
Retail,
Management,
Pharmaceutical industry,
Indu EverythingALS and CureALS, two prominent organizations dedicated to finding a cure for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), are thrilled to announce their merger and unified operations on the EverythingALS platform.
Key Points:
- EverythingALS and CureALS, two prominent organizations dedicated to finding a cure for Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD), are thrilled to announce their merger and unified operations on the EverythingALS platform.
- Both EverythingALS and CureALS have identified key areas of alignment that have propelled this unification, based on a common vision, and understanding of the challenges faced in the cure of ALS.
- Expressing her confidence in the merger, Indu stated, "CureALS is EverythingALS's vehicle to focus on research to discover a cure, without overlap in approach.
- The merger between EverythingALS and CureALS represents a significant leap forward in the pursuit of a cure for ALS and FTD.
Retrieved on:
Monday, September 19, 2022
Gait,
Neuro,
Algorithm,
Senior advisor,
Amyotrophic lateral sclerosis,
Spirometry,
Neurodegeneration,
Speech,
Organization,
Radcliffe,
Partnership,
Amyotrophy,
Person,
Patient,
Physical disability,
Physician,
CEO,
Running,
Walking,
Lists of diseases,
Solution,
Diagnosis,
Caregiver,
Gait analysis,
SAN,
ALS,
Research,
AI,
Disease,
Medical device SAN FRANCISCO, Sept. 19, 2022 /PRNewswire-PRWeb/ -- EverythingALS, a patient-focused non-profit that brings together people living with ALS, caregivers, physicians, researchers, and pharmaceutical companies to collaborate on an open innovation platform using cutting-edge technologies and data science to improve progression measurements for neurological disease like Amyotrophic Lateral Sclerosis (ALS), has initiated a new study, The Radcliff Study, with partners in the quest to find a diagnosis, treatment, and cure for ALS. EverythingALS is teaming up with Aural Analytics, a leader in clinical-grade speech analytics, FeetMe, a medical device company that produces smart and connected insoles for improved running, walking and gait analysis, ZEPHYRx, a leading provider of end-to-end remote respiratory monitoring solutions, and a major pharmaceutical company. The Radcliff Study is a novel research-as-a-feasibility study to inform the likelihood of success for a pre-competitive collaboration focused on developing an end-to-end digital alternative for the ALSFRS-R that supports clinically meaningful outcomes tailored for use in ALS. There is not one test or procedure to establish the diagnosis of ALS and there is also no known cure or treatment options available.
Key Points:
- The Radcliff Study is a multidisciplinary study focused on gait analysis, pulmonary function testing, and speech analytics to make strides towards a digital biomarker.
- The study uses AI, remote patient monitoring technologies, and algorithms to determine possibly clinically meaningful characteristics for persons living with ALS.
- "EverythingALS is excited to work with Aural Analytics, FeetMe and ZEPHYRx on this unique study," said Indu Navar, Founder of the Peter Cohen Foundation and CEO of EverythingALS.
- "We're thrilled to be a part of this research study as spirometry is an important indicator of ALS disease progression."
Motion,
Amyotrophic lateral sclerosis,
Diagnosis,
Lists of diseases,
Physician,
Business,
Neurodegeneration,
CEO,
VP,
Forward-looking statement,
Parkinson's disease,
Research,
Biomarker,
Alzheimer's disease,
Johns Hopkins University,
Therapy,
Safety,
Nature,
Amyotrophy,
NASDAQ,
Drug development,
ALS,
Disease,
Caregiver,
Patient,
Investor,
LINK,
Motivation,
Pharmaceutical industry,
Medical device,
EU LOS ALTOS, Calif. and CAMBRIDGE, Mass., Aug. 2, 2022 /PRNewswire/ -- EverythingALS, a patient-focused non-profit that brings together patients, caregivers, physicians, researchers, and pharmaceutical companies using technological innovations and data science to support efforts to improve care for those living with a neurological disease like Amyotrophic Lateral Sclerosis (ALS), today announced NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, as a new collaborator in the effort to identify treatments and a cure for ALS.
Key Points:
- "We are excited to be working with NeuroSense Therapeutics," said Indu Navar, Founder of the Peter Cohen Foundation, functioning as EverythingALS.
- "EverythingALS and NeuroSense are taking similar actions in the fight against neurological diseases, including conducting extensive biomarker research.
- "As we prepare to enroll patients in the US and EU for our PARADIGM Phase IIb study, we are increasing our engagement with the international ALS community," added Mr. Ben Noon.
- NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases.
